Michael Lübbert
#143,026
Most Influential Person Now
Michael Lübbert's AcademicInfluence.com Rankings
Michael Lübbertphilosophy Degrees
Philosophy
#7557
World Rank
#10789
Historical Rank
Logic
#4607
World Rank
#5920
Historical Rank
Michael Lübbertbiology Degrees
Biology
#10228
World Rank
#13536
Historical Rank
Biochemistry
#1603
World Rank
#1735
Historical Rank
Download Badge
Philosophy Biology
Michael Lübbert's Degrees
- Doctorate Medicine Harvard University
Why Is Michael Lübbert Influential?
(Suggest an Edit or Addition)Michael Lübbert's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. (2007) (750)
- Acute Myeloid Leukemia: Epidemiology and Etiology (2006) (612)
- New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. (2012) (587)
- Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. (2000) (565)
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. (2012) (539)
- Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. (2002) (506)
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey (2015) (423)
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. (2011) (413)
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy (2010) (394)
- Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. (2011) (364)
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. (2014) (343)
- CXCR4 is a prognostic marker in acute myelogenous leukemia. (2007) (304)
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells (2009) (296)
- Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy (2016) (295)
- Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. (2011) (282)
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
- Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. (2010) (247)
- High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. (2010) (243)
- Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine (2001) (234)
- Upstream and downstream targets of RUNX proteins (2003) (228)
- Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. (1990) (216)
- Epigenetic targets in hematopoietic malignancies (2003) (215)
- Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. (2000) (211)
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. (2014) (206)
- Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. (2019) (205)
- A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy (2012) (198)
- DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats (2017) (195)
- N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. (1993) (194)
- DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. (2000) (189)
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. (2010) (187)
- ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat (2015) (185)
- DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. (2002) (176)
- Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells. (1991) (175)
- Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome (2013) (173)
- Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. (2008) (163)
- The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. (2010) (158)
- Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). (2013) (156)
- Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) (2005) (156)
- Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. (2001) (152)
- Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. (2006) (148)
- Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (2017) (141)
- Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. (1989) (140)
- Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. (2011) (138)
- Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms (2005) (126)
- Clinical development of demethylating agents in hematology. (2014) (125)
- Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. (2010) (123)
- Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q (2011) (121)
- Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). (2006) (118)
- Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
- CD34− Hematopoietic Stem Cells: Current Concepts and Controversies (2003) (112)
- Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. (2005) (110)
- Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes (2009) (110)
- Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. (2003) (109)
- Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. (2003) (106)
- Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. (2011) (105)
- N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. (1990) (105)
- An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients (2005) (103)
- Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting (2010) (101)
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. (1989) (98)
- Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (2017) (98)
- Current status of epigenetic treatment in myelodysplastic syndromes (2008) (96)
- Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. (2000) (92)
- The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. (2004) (92)
- Cyclin A1 expression in leukemia and normal hematopoietic cells. (1999) (92)
- Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients (2009) (88)
- Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (88)
- Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). (2013) (86)
- Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups (2008) (85)
- Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (2013) (85)
- Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. (1991) (82)
- Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions (2019) (78)
- DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. (2005) (78)
- Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (2015) (77)
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure (2017) (76)
- p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression (1988) (75)
- Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. (1991) (75)
- Complementing mutations in core binding factor leukemias: from mouse models to clinical applications (2008) (74)
- CD34+ or CD34−: which is the more primitive? (2002) (74)
- Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. (2010) (74)
- Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-α (2005) (71)
- Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial (2018) (70)
- Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload (2012) (70)
- RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia (2017) (70)
- Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. (2005) (69)
- Control of tetrahydrobiopterin synthesis in T lymphocytes by synergistic action of interferon-gamma and interleukin-2. (1990) (67)
- Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. (2005) (66)
- Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. (2009) (64)
- Superiority of prolonged low‐dose azanucleoside administration? (2006) (64)
- Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation (2020) (64)
- Generalized herpes simplex virus infection in an immunocompromised patient--report of a case and review of the literature. (2005) (63)
- Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML (1998) (63)
- DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. (2006) (62)
- Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy (2015) (62)
- Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. (2014) (62)
- Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group. (2019) (61)
- 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft (2015) (61)
- Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies (2021) (60)
- Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study (2018) (59)
- DNA Methylation as a Therapeutic Target in Hematologic Disorders: Recent Results in Older Patients with Myelodysplasia and Acute Myeloid Leukemia (2004) (59)
- Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. (2017) (56)
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. (2021) (55)
- Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis (1999) (54)
- The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells (2015) (54)
- Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation (2018) (54)
- All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study (2016) (54)
- Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes (2015) (53)
- Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells. (1988) (53)
- Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. (2007) (51)
- Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. (2011) (51)
- Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) (2016) (50)
- Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature (2004) (48)
- Monosomal karyotype in MDS: explaining the poor prognosis? (2013) (48)
- Allelic loss in the progression of myelodysplastic syndrome. (2000) (47)
- Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans (2020) (46)
- Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. (2005) (46)
- Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia (2013) (46)
- DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. (2017) (46)
- HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. (2012) (45)
- Valuation of transfusion-free living in MDS: results of health utility interviews with patients (2009) (45)
- The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO (2011) (45)
- Mechanisms of p53 alteration in acute leukemias. (1994) (45)
- Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives (2016) (45)
- Quantitative analyses of DAPK1 methylation in AML and MDS (2012) (45)
- Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia (1992) (44)
- Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia (2017) (44)
- Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature (2005) (44)
- Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells (2008) (44)
- Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. (1992) (44)
- p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies (2002) (43)
- LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML (2019) (43)
- Leukemogenic AML1‐ETO fusion protein upregulates expression of connexin 43: The role in AML1‐ETO‐induced growth arrest in leukemic cells (2006) (43)
- Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis (2017) (43)
- Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? (2003) (42)
- Clinical Results of Hypomethylating Agents in AML Treatment (2014) (42)
- Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) (2003) (40)
- Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study (2003) (40)
- Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. (2007) (40)
- Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7 (2002) (40)
- Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis (2006) (40)
- All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial (2011) (39)
- Quality assurance in RT-PCR-based BCR/ABL diagnostics – results of an interlaboratory test and a standardization approach (2000) (39)
- Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. (2002) (39)
- Expression of leukemia inhibitory factor is regulated in human mesenchymal cells. (1991) (38)
- Williams–Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO (2004) (38)
- Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606) (2015) (38)
- Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group (2010) (38)
- Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS (2020) (37)
- Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. (2003) (37)
- ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO (2006) (36)
- The role of Ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation (2000) (35)
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia (2016) (35)
- Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. (2012) (35)
- A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia (2013) (34)
- Side-population cells from different precursor compartments. (2003) (34)
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. (2020) (34)
- Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. (2019) (34)
- ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG (2012) (34)
- A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias. (1992) (33)
- Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia (2014) (33)
- Leukemia targeting ligands isolated from phage display peptide libraries (2007) (33)
- Epigenetic lesions in malignant melanoma. (2007) (32)
- Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group (2016) (32)
- Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. (2019) (32)
- Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. (2018) (32)
- Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine). (2004) (32)
- Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2010) (31)
- Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up (2008) (30)
- Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis (2006) (30)
- Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the ‘second hit’ hypothesis (2008) (30)
- Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. (1996) (30)
- Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (2014) (29)
- Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia (2014) (28)
- Expression, methylation and chromatin structure of the p53 gene in untransformed and human T-cell leukemia virus type I-transformed human T-lymphocytes. (1989) (28)
- BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1). (2010) (28)
- Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. (2018) (28)
- Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) (2016) (27)
- CXCR 4 is a prognostic marker in Acute Myelogenous Leukemia (2006) (27)
- Tracing the development of acute myeloid leukemia in CBL syndrome. (2014) (26)
- In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies (2005) (26)
- Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia (1990) (25)
- Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31–q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study (2005) (25)
- Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia (2018) (25)
- Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. (2013) (25)
- Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO (2008) (25)
- Decitabine in acute myeloid leukemia. (2005) (25)
- Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). (2003) (25)
- Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. (2007) (24)
- Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. (2020) (24)
- Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells (2006) (23)
- Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis (2014) (23)
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. (2020) (23)
- Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia (2011) (23)
- Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial (2016) (23)
- Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells (2014) (23)
- Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges (2015) (23)
- Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat (2013) (22)
- Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study. (2005) (22)
- Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. (2005) (22)
- Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group (2015) (21)
- Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing (2016) (21)
- Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy (2008) (21)
- Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy (2017) (20)
- Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO‐mediated lysozyme repression (2006) (19)
- Differential regulation of interleukin‐6 expression in human fibroblasts by tumor necrosis factor‐α and lymphotoxin (1990) (19)
- Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine (2010) (19)
- Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib (2010) (19)
- Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer. (2008) (19)
- Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. (2013) (19)
- Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients (2014) (18)
- Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS). (2005) (17)
- Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5‐aza‐2′‐deoxycytidine (Decitabine) (2017) (17)
- Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid (2015) (17)
- Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group (2017) (17)
- Corrigendum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (Leukemia (2016) 30 (1672-1681) DOI: 10.1038/leu.2016.69) (2016) (17)
- Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML (1999) (16)
- Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients (2016) (16)
- Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. (2015) (16)
- MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells. (2013) (16)
- Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. (2015) (16)
- Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. (1992) (16)
- Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy. (2005) (16)
- Cytosine demethylation of the proteinase-3/myeloblastin primary granule protease gene during phagocyte development (1999) (16)
- Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). (2018) (16)
- Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment (2018) (16)
- Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG) (2016) (15)
- Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. (2018) (15)
- N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6. (1993) (15)
- Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. (1997) (15)
- Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia (2017) (15)
- HTLV-I-associated adult T cell leukemia/lymphoma in two patients from Bucharest, Romania. (1996) (15)
- Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS. (2005) (15)
- Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications (2010) (15)
- Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia (2020) (14)
- Interleukin‐4 regulates mRNA accumulation of macrophage‐colony stimulating factor by fibroblasts: synergism with interleukin‐1β (1990) (13)
- Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation (2011) (13)
- Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency (2015) (13)
- Immunotherapy in adult acute leukemia. (2017) (13)
- Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report (2020) (13)
- The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation (1997) (13)
- Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. (2006) (13)
- Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. (2016) (13)
- Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia (2003) (12)
- The silence of the genes: epigenetic disturbances in haematopoietic malignancies (2005) (12)
- Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients. (2006) (12)
- Expression of the Fas antigen on primary human leukemia cells (2005) (12)
- Stable methylation patterns of MYC and other genes regulated during terminal myeloid differentiation. (1991) (12)
- The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. (2014) (12)
- Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q). (2009) (12)
- Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. (2006) (12)
- Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series (2014) (12)
- Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML (2020) (12)
- The epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy (2021) (11)
- Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? (2010) (11)
- Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction (2021) (11)
- Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy. (2012) (11)
- Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. (2007) (11)
- CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial (2016) (11)
- Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome (2018) (11)
- Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome (2020) (10)
- Estimating and comparing adverse event probabilities in the presence of varying follow‐up times and competing events (2020) (10)
- Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
- Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib (2016) (10)
- Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha. (1995) (10)
- [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis]. (2000) (10)
- Re-Treatment with Low-Dose 5-Aza-2′-Deoxycytidine (Decitabine) Results in Second Remissions of Previously Responsive MDS Patients. (2004) (10)
- Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administration. (1990) (10)
- Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial. (2004) (10)
- Successful treatment of disseminated central nervous aspergillosis in a patient with acute myeloblastic leukemia. (1997) (10)
- Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine (2005) (10)
- Can we predict responsiveness to hypomethylating agents in AML? (2019) (10)
- AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms (2021) (10)
- Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis (2021) (10)
- Myelodysplastic syndromes. (2004) (9)
- An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2015) (9)
- Epigenetic therapy in MDS and acute AML: focus on decitabine (2005) (8)
- ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes (2014) (8)
- The role of X‐inactivation in the gender bias of patients with acquired α‐thalassaemia and myelodysplastic syndrome (ATMDS) (2009) (8)
- Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (2011) (8)
- Myelodysplastic syndrome with complex karyotype associated with long‐term highly active antiretroviral therapy (2009) (8)
- Combined targeting of the epigenetic silence in leukemia: cooperating activities of DNA methylation and histone deacetylation inhibitors. (2005) (8)
- Differentiation associated modulation of the cytokine and chemokine expression pattern in human myeloid cell lines. (2001) (8)
- Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials (2017) (8)
- Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma (1997) (8)
- Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (8)
- Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications (2022) (7)
- Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2019) (7)
- Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial (2017) (7)
- Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group (2015) (7)
- Netboost: Boosting-Supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington’s Disease (2019) (7)
- Growing evidence for an underestimation of poor-risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes (2007) (7)
- Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation (2008) (7)
- When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. (2013) (7)
- Familial and metachronous malignant lymphoma: Absence of constitutional p53 mutations (1999) (7)
- Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia‐chromosome positive chronic myeloid leukemia (CML) (2009) (7)
- Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
- Epigenetic Therapy of Cancer (2014) (7)
- Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors (2019) (7)
- Retrospective analysis of ras gene activation in myeloid leukemic cells. (1990) (7)
- Targets of epigenetic therapy – Gene reactivation as a novel approach in MDS treatment (2007) (7)
- Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials (2020) (6)
- Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML) (2013) (6)
- Cytokines in the pathogenesis and management of non-Hodgkin's lymphomas. (1991) (6)
- Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. (2019) (6)
- No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation (2013) (6)
- Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin (2021) (6)
- Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS (2016) (6)
- The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia (2017) (6)
- Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. (2006) (6)
- The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia (2005) (5)
- Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes (2019) (5)
- Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes (2017) (5)
- Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia (2020) (5)
- Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial (2008) (5)
- Occurrence of a germinoma 22 years after resection of a mature cerebral teratoma (2008) (5)
- A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia (2018) (5)
- Nitroreductase‐Mediated Release of Inhibitors of Lysine‐Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells† (2019) (5)
- Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality? (2010) (5)
- A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1 (2013) (5)
- Detection of allele‐specific expression of N‐RAS oncogenes in human leukaemia cells (1992) (5)
- Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement. (1998) (5)
- The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation (2022) (4)
- Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) (2012) (4)
- Sorafenib Promotes Graft-Versus-Leukemia Activity in Mice and Humans through IL-15 Production in Leukemia Cells (2016) (4)
- Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial (2018) (4)
- Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factor. (1990) (4)
- Clonal analysis of n-ras gene activation in acute myeloid leukemia. (1993) (4)
- Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT. (2004) (4)
- Increased numbers of bone marrow blasts in acute myeloid leukaemia patients treated with G-CSF after chemotherapy. (1997) (4)
- Lethal systemic herpes simplex virus type 1 infection during chemotherapy for acute lymphoblastic leukaemia (1999) (4)
- The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia (2021) (3)
- Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia (2020) (3)
- Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia. (2019) (3)
- Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (2010) (3)
- Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study. (2009) (3)
- Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome. (2008) (3)
- Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation (2016) (3)
- Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (2012) (3)
- The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. (2017) (3)
- First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience (2021) (3)
- Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient. (1999) (3)
- Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2016) (3)
- Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group (2018) (3)
- Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial (2008) (3)
- Decitabine: Where Is the Target?. (2005) (3)
- NHR4 domain mutations of ETO are probably very infrequent in AML1–ETO positive myeloid leukemia cells (2010) (3)
- Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group (2013) (3)
- Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor. (2000) (3)
- Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R (2014) (2)
- 8 Geriatric assessment: a prospective study in older patients with AML and high-risk MDS (2006) (2)
- Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study (2013) (2)
- 10-day vs 5-day decitabine: equivalence cannot be concluded. (2019) (2)
- Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance (2018) (2)
- Efficacy of a 3-Day, Low-Dose Treatment with 5-Azacytidine Followed by Donor Lymphocyte Infusions (DLI ) in Older AML/MDS Patients Relapsed after Allografting. (2008) (2)
- Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia (2012) (2)
- P.11 Multidimensional geriatric assessment in elderly patients with MDS/AML (2007) (2)
- Innovative strategies for adverse karyotype acute myeloid leukemia (2017) (2)
- Differential regulation of interleukin-6 expression in human fibroblasts by tumor necrosis factor-alpha and lymphotoxin. (1990) (2)
- Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications (2021) (2)
- Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein (2008) (2)
- Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial) (2022) (2)
- A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1). (2022) (2)
- Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status (2021) (2)
- Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia (2022) (2)
- P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients (2007) (2)
- The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells (2015) (2)
- FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype (2010) (2)
- Development of a Frailty Score for Older Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. (2009) (2)
- S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG) (2019) (2)
- Multiple hypermethylated genes are potential in vivo targets of demethylating agents (2003) (2)
- Erratum: DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats (2017) (2)
- Lsd1 inhibition induces differentiation and decreases leukemic stem cell frequency in Hoxa9/Meis1-driven AML (2017) (2)
- Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins (2014) (2)
- Cancer Testis Antigens Residing on the X-Chromosome Are Preferentially Derepressed in Myeloid Leukemic Cells by the DNA Demethylating Agent 5-Aza-2’-Deoxycytidine (DAC). (2008) (2)
- Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17‐10 CIARA trial) (2018) (2)
- Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG) (2015) (1)
- Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study (2013) (1)
- Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification (2010) (1)
- Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients (2018) (1)
- Aggressive plasmablastic lymphoproliferation complicated by hemophagocytic syndrome 12 years after heart transplant (2012) (1)
- Inducible AML1/ET0 Expression in U-937 Myeloid Cells: a Model to Identify Genes Targeted by the Leukemia-Specific Fusion Protein (2003) (1)
- Treatment of Hematologic Malignancies with DNA Hypomethylating Agents (2014) (1)
- Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine (2020) (1)
- LSD1 Inhibition Leads to Differentiation in Hoxa9/Meis1- but Not in MN1-Induced Acute Myeloid Leukemia (2017) (1)
- Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients (2022) (1)
- LSD1 Inhibition Induces Differentiation and Reduces the Frequency of Leukemia-Initiating Cells in Hoxa9/Meis1-Induced Acute Myeloid Leukemia (2016) (1)
- Autologous hematopoietic stem cell transplantation for myelodysplastic syndromes: which cell source is preferable? (2006) (1)
- Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies (2008) (1)
- Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA (2017) (1)
- P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA (2022) (1)
- Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation (2019) (1)
- Chromatin and DNA Methylation Changes of the Human Myeloperoxidase Gene During Myeloid Differentiation (1990) (1)
- P-111 Time changes in predictive power of MDS prognostic scores – Effects on revised scores such as the IPSS-R, impact of age (2013) (1)
- Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. (2003) (1)
- A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients. (1998) (1)
- Allogeneic Stem Cell Transplantation - A Long-Term Curative Approach In Patients ≥ 60 Years With Advanced Disease AML/MDS, - The Freiburg Experience Of 250 Consecutive Patients (2013) (1)
- [Epigenetic changes in malignant cells]. (2011) (1)
- CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study (2012) (1)
- Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes (2022) (1)
- P-108 Re-treatment results insecond remission of MDS with previous response to low-dose 5-aza-2′-deoxycytidine (decitabine) (2005) (1)
- Myeloperoxidase: Gene Demethylation and Expression in Acute Myeloid Leukemias (1992) (1)
- Acute myeloid leukemia of the elderly: results of induction after previous treatment of high-risk myelodysplastic syndrome with a demethylating agent (2003) (1)
- DNA Demethylating Agents: Clinical Uses (2004) (1)
- Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab (2021) (1)
- A multicenter phase II trial of Decitabine as first-line treatment of older patients with acute myeloid leukemia judged unfit for induction chemotherapy Running head: First-line DAC for older AML patients unfit for induction (2011) (1)
- Cytokines and myeloid-specific genes: patterns of expression and possible role in proliferation and differentiation of acute myelogenous leukemia cells. (1993) (1)
- Azanucleoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia (2016) (1)
- Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2021) (1)
- Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML. (2005) (1)
- Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML) (2019) (1)
- Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial (2014) (0)
- The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression (2021) (0)
- MDS progression to AML associates with acquisition of single driver mutations with consequent changes in clonal architecture and occurrence of multiple clones with mutations in identical genes (2017) (0)
- P-316 TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial (2013) (0)
- Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups (2012) (0)
- Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment (2022) (0)
- O-023 Did the prognosis of MDS patients improve during the last 30 years? (2013) (0)
- Erratum: Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression (Blood (1991) 78 (2070)) (1999) (0)
- Therapeutic Granulocyte Transfusions in Neutropenic Patients with Invasive Pulmonary Aspergillosis (2011) (0)
- [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]. (2010) (0)
- PHM20 VALUE OF TRANSFUSION-FREE LIVING IN MDS: RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS (2007) (0)
- P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q) (2009) (0)
- Decitabine (DAC) Treatment Induces Very Early In Vivo DNA Methylation and Transcriptome Changes in Primary AML Peripheral Blood Blasts (2011) (0)
- DNA‐modifying Enzymes (2019) (0)
- AML1/ETO-Mediated Lysozyme Repression Is Independently Relieved by Inhibitors of DNA Methylation and Histone Deacetylation. (2006) (0)
- Implantation of Patient-Derived Acute Leukemia Cells into the Hematopoietic Niche of Immunocompromised Mice Favors Faithful Recapitulation of the Disseminated Growth of Human Leukemia (2017) (0)
- 166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study (2011) (0)
- Single Cell Genotyping of Inv(16) AML in CBL Mutated Clonal Hematopoiesis Characterizes Clonal Architecture and Evolution of Exome Sequencing-Identified Mutations in the Protein Tyrosine Phosphatase Ptprt and Other Genes (2015) (0)
- Acknowledgement to referees (2006) (0)
- Combination Treatment of AML Cells with Dnmt and HDAC Inhibitors: Synergistic Target Gene Downregulation Associated with Gene Body Demethylation (2015) (0)
- Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT). (2009) (0)
- Epigenetic therapy in MDS and AML: focus on decitabine (2006) (0)
- Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) (2021) (0)
- Low-Dose 5-Azacytidine Combined With Donor Lymphocyte Infusions (DLI), An Effective Outpatient Treatment Of AML/MDS Relapse After Allografting, Can Induce Long-Term Remissions: An Experience Of 72 Patients (2013) (0)
- Optimizing epigenetic therapy for myelodysplastic syndromes: issues and strategies. (2009) (0)
- P-313 Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide (2013) (0)
- In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response (2014) (0)
- Cooperative Effects of a Dnmt Inhibitor and All-Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara (2018) (0)
- Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia (2021) (0)
- Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis (2010) (0)
- Two novel somatic mutations of the ATRX gene in female patients with acquired alpha thalassemia of myelodysplastic syndrome (ATMDS). (2006) (0)
- Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia (2014) (0)
- In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. (2023) (0)
- MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS. (2022) (0)
- Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia (2013) (0)
- Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts <10G/L (2014) (0)
- RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia (2017) (0)
- Identi fi cation of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia (2019) (0)
- In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific? (2018) (0)
- Animal models for the biological effects of continuous high cytokine levels (1990) (0)
- Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy (2016) (0)
- Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome (2013) (0)
- Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG) (2018) (0)
- C013 The influence of therapeutic strategies on survival in distinct cytogenetic subgroups – A collaborative study based on 3860 patients with MDS (2007) (0)
- Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification (2018) (0)
- ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes (2013) (0)
- XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. (2008) (0)
- OP21 Epigenetic therapy in the biological continuum of MDS and AML (2007) (0)
- Role of Bcl‐2 inhibition in myelodysplastic syndromes (2022) (0)
- Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients ≤60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. (2006) (0)
- Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2021) (0)
- Induction of an Erythroid but Not Megakaryocytic Expression Signature in Myeloid Cells By in Vitro 5-Aza-2'-Deoxycytidine Treatment (2015) (0)
- Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia (2003) (0)
- Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG) (2019) (0)
- Progression of Mds to Aml Features Gain of Single Driver Mutations with Consequent Changes in Clonal Composition and Occurrence of Multiple Clones with Mutations in Identical Genes (2017) (0)
- The Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) Is Epigenetically Regulated in AML and Suppresses Leukemia Cell Growth (2014) (0)
- P-277 Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011 (2013) (0)
- Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011 (2012) (0)
- 175 Low dose 5-AZA-′2-deoxycytidine in eldery patients with high risk MDS (1997) (0)
- Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). (2023) (0)
- P120 The development of a frailty index for elderly patients with MDS (2007) (0)
- Impact of Distinct Genetic and Epigenetic Aberrations on Survival and Response in Acute Myeloid Leukemia Patients Receiving Epigenetic Therapy (2016) (0)
- Acute Panmyelosis with Myelofibrosis: An Evaluation of Distinctive Clinicopathological Features Including Bone Marrow Stroma. (2005) (0)
- Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML (2019) (0)
- Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia Characterization and Prognostic Relevance (2010) (0)
- Epigenetic Drug Treatment Globally Induces Cryptic Transcription Start Sites Encoded in Long Terminal Repeats (2016) (0)
- AML1/ETO Expresssion in Myeloid Leukemia Cells Is Associated with Enhanced Growth-Inhibitory and P15/INK4b Demethylating Effects of 5-AZA-2′-Deoxycytidine. (2004) (0)
- TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial (2013) (0)
- A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (2010) (0)
- Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia (2018) (0)
- Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS (2018) (0)
- DNA Methylation and Epigenetics: New Developments in Biology and Treatment (2019) (0)
- Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia (2022) (0)
- Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network (2022) (0)
- 119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry) (2011) (0)
- Treatment of relapsed non-Hodgkin’s lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation (1997) (0)
- All-Trans retinoic Acid Enhances the Antileukemic Activity of Decitabine and Venetoclax in Non-M3 AML Cells (2022) (0)
- ' s response to reviews Title : The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and-wildtype non-small cell lung cancer cells (2014) (0)
- Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction (2021) (0)
- An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1 (2013) (0)
- Frequent methylation of p15 5′ region in leukemic and preleukemic disorders, and reduction of p15 methylation levels by 5-aza-deoxycytidine treatment is correlated with clinical remission (1996) (0)
- Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients. (2006) (0)
- Risk Factors for Delayed Engraftment, Infections and TRM in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation with Highly Selected CD34+ Cells (2002) (0)
- AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients. (2022) (0)
- Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α. (2004) (0)
- Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells (2010) (0)
- Acute myeloid leukemia LSD 1 inhibition by tranylcypromine derivatives interferes with GFI 1-mediated repression of PU . 1 target genes and induces differentiation in AML (2019) (0)
- Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: P53-Independent Upregulation of P21/WAF/CIP1. (2004) (0)
- O-022 Clinical features, treatment and prognosis in patients with MDS and monosomy 7 (2013) (0)
- Influence of Different Genetic Alterations On the Engraftment Capacity and Serial Transplantation Efficiency of AML Patient-Derived Bone Marrow and Peripheral Blood Cells in NSG Mice (2012) (0)
- Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients (2021) (0)
- Hematopoietins: New Tools in the Treatment of Hematopoietic Insufficiency (1993) (0)
- 347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial (2011) (0)
- 11 A panel of patient derived xenograft models of different haematological malignancies suitable for preclinical drug screening campaigns (2014) (0)
- Analysis of Efficacy and Costs of Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Leukemia: “Real Life” Evaluation (2011) (0)
- Poster: AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients (2022) (0)
- Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial (2010) (0)
- EORTC Leukemia Group achievements (2012) (0)
- Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial (2010) (0)
- Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC) (2016) (0)
- Invited lecture: Low-dose DNA demethylating agents as nonintensive treatment option in MDS (2006) (0)
- Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2013) (0)
- Topic: AS02-Epidemiology (2021) (0)
- Sequential Cytogenetic Analysis of 322 Patients with Myelodysplastic Syndromes. Delineation of Genetic Evolution and Clinical Implications. (2004) (0)
- Treatment of high-risk MDS patients: State of the art (2014) (0)
- Williams-Beuren Syndrome Critical Region-5/Non-T Cell Activation Linker: A Novel Target Gene of AML1/ETO. (2004) (0)
- Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models (2019) (0)
- Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines. (2009) (0)
- C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome (2009) (0)
- Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2014) (0)
- Single cell genotyping and epigenotyping of acute myeloid leukemia (2016) (0)
- 120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q) (2015) (0)
- Epigenetic therapy for myelodysplastic syndromes has entered center stage. (2009) (0)
- Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA) (2016) (0)
- O-33 Cryogenetic profile in 2124 patientswith MDS — Correlations with morphology, clinical course and prognosis (2005) (0)
- P-10 Influence of age and gender on survival in MDS: Importance of an IPSS*gender interaction — A multicenter analysis on 1159 patients (2005) (0)
- A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial (2014) (0)
- Absence of early platelet increment in healthy mice during decitabine treatment (2022) (0)
- Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease. (2009) (0)
- Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine (2011) (0)
- Synergistic Reactivation Of Cancer/Testis Antigens By Combination Treatment With Decitabine and Histone Deacetylase Inhibitors (Valproate, Panobinostat) In Myeloid Leukemia Cells (2013) (0)
- O-22 Incidence of cytogenetic response in MDS/AML patients with complex karyotype receiving low-dose 5-aza-2′deoxycytidine (decitabine) treatment (2005) (0)
- Identification of a Novel Chromosomal Translocation t(11;16)(q23;q22) Fusing MLL to Enhancer of mRNA Decapping (EDC)-4 in Smoldering Acute Myeloid Leukemia (2016) (0)
- PB1731 ELEVATED FETAL HEMOGLOBIN (HBF) IN ELDERLY AML PATIENTS RECEIVING HYPOMETHYLATING AGENTS: ENHANCEMENT OF HBF INDUCTION BY RETINOIC ACID? (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Lübbert?
Michael Lübbert is affiliated with the following schools:
